Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $14.6 million.

  • Kymera Therapeutics' Other Accumulated Expenses rose 1540.6% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 1540.6%. This contributed to the annual value of $17.8 million for FY2024, which is 1789.52% up from last year.
  • Kymera Therapeutics' Other Accumulated Expenses amounted to $14.6 million in Q3 2025, which was up 1540.6% from $16.7 million recorded in Q2 2025.
  • Kymera Therapeutics' Other Accumulated Expenses' 5-year high stood at $17.8 million during Q4 2024, with a 5-year trough of $8.0 million in Q1 2024.
  • In the last 5 years, Kymera Therapeutics' Other Accumulated Expenses had a median value of $14.1 million in 2025 and averaged $13.6 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 23218.24% in 2021, then crashed by 3217.4% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Other Accumulated Expenses (Quarter) stood at $15.2 million in 2021, then grew by 11.91% to $17.0 million in 2022, then fell by 11.05% to $15.1 million in 2023, then increased by 17.9% to $17.8 million in 2024, then fell by 18.23% to $14.6 million in 2025.
  • Its Other Accumulated Expenses was $14.6 million in Q3 2025, compared to $16.7 million in Q2 2025 and $14.1 million in Q1 2025.